Consumer healthcare company Haleon plc has announced that a new Haleon site in India expected to open in early 2028. Aimed at strengthening regional supply networks and meeting rising healthcare demands, the new Haleon facility in India to create up to 500 jobs across engineering, manufacturing, and distribution.
NEW DELHI, INDIA — Consumer healthcare multinational Haleon plc announced on Monday, June 8, 2026, its plan to significantly expand its industrial presence in South Asia with a new manufacturing facility. According to corporate growth projections, the new Haleon site in India expected to open in early 2028. Strategically designed to strengthen the company’s regional supply chain, the development of the new Haleon facility in India to create up to 500 jobs across specialized manufacturing, engineering, and administrative roles. This major capital investment highlights India's growing importance as a global hub for pharmaceutical and over-the-counter (OTC) consumer health production.
Expanding Manufacturing Infrastructure in South Asia
The decision to establish a new greenfield production facility reflects a broader trend among global healthcare corporations to locate manufacturing operations closer to rapidly expanding consumer bases. Haleon, widely recognized for its prominent global portfolio of consumer healthcare brands—including Sensodyne, Panadol, Advil, and Centrum—intends to use this upcoming hub to secure long-term capacity requirements.
Scheduled for operational launch in the first quarter of 2028, the state-of-the-art facility will integrate advanced digital manufacturing technologies, automated packaging lines, and sustainable environmental systems. By boosting its domestic industrial footprint, Haleon aims to minimize logistical transit latencies and insulate its regional business units from global shipping bottlenecks that have intermittently impacted cross-border consumer goods trade.
Employment Generation and Local Economic Impact
The upcoming production facility is poised to deliver a substantial economic boost to its host region through job creation and human capital development. Corporate planners confirmed that the new Haleon facility in India to create up to 500 jobs.
The projected employment opportunities will span a diverse range of proficiencies:
Technical Engineering: Roles in industrial automation, chemical engineering, and predictive maintenance systems.
Quality Assurance: Positions in strict compliance monitoring, laboratory analysis, and WHO-GMP standards enforcement.
Logistics & Supply Chain: Jobs in automated warehousing, inventory management, and regional distribution coordination.
Administration: Roles in facility operations, corporate governance, human resources, and local procurement.
Beyond direct employment, the establishment of the site is expected to generate thousands of secondary jobs within localized ecosystem networks, benefiting regional construction firms, raw material suppliers, and technical services providers.
Impact on Consumers, Businesses, and Market Investors
For Regional Consumers and Retailers
Once the new Haleon site in India expected to open in early 2028, local consumers will benefit from more reliable, uninterrupted access to essential self-care and over-the-counter products. Retail pharmacies and supermarkets will see a stabilized inventory flow, reducing localized out-of-stock scenarios for high-demand consumer health goods.
For B2B Supply Partners
Domestic raw material stockists, packaging manufacturers, and specialized transport agencies will gain a reliable, long-term multinational client. Haleon’s strict global procurement rules will likely push local suppliers to elevate their own manufacturing standards to match international benchmarks.
For Global Capital Investors
Institutional investors view the expansion as a calculated move to capture a greater share of the growing healthcare spend in emerging Asian economies. By shifting more production into a cost-efficient manufacturing environment, Haleon stands to optimize its long-term operating margins and enhance capital returns for its global shareholders.
Official Sources Section
The operational timelines, job metrics, and regional capacity forecasts used in this report align with corporate development briefs, project notices, and global capacity management statements issued by Haleon plc.
Quote Section
In strategic statements outlining the long-term industrial path of the company's consumer health portfolio, corporate planning executives stated:
"The establishment of the new Haleon site in India expected to open in early 2028 represents a key component of our global infrastructure roadmap. This capital investment allows us to scale up our regional manufacturing capabilities to ensure we meet the evolving health and wellness needs of millions of consumers."
Reflecting on the socioeconomic contributions to the host region, project managers added:
"The development of the new Haleon facility in India to create up to 500 jobs, bringing advanced technical roles and localized employment stability. We are fully committed to fostering local talent and building a sustainable, high-performance workspace."
Why It Matters
The practical implications of Haleon's industrial expansion stretch far beyond simple manufacturing statistics. As emerging markets experience a rise in disposable income and a growing awareness of preventative healthcare, the demand for verified, high-quality over-the-counter medical solutions is climbing rapidly. Building a major production hub allows Haleon to bypass global freight complexities, shield its supply chains from sudden tariff modifications, and bring critical self-care products to market at competitive price points.
Key Facts at a Glance
Project Developer: Haleon plc (LSE/NYSE:
Haleon)
Target Operational Window: The new Haleon site in India expected to open in early 2028.
Direct Employment Generation: The new Haleon facility in India to create up to 500 jobs.
Operational Mandate: Production of prominent consumer healthcare, oral care, and OTC products.
Strategic Objectives: Optimizing regional supply chains and capturing expanding market demand in Asia.
FAQ Section
When is the new Haleon site in India expected to begin operations?
The new Haleon site in India expected to open in early 2028, following the completion of greenfield construction and rigorous regulatory equipment validations.
What kind of employment opportunities will the upcoming facility generate?
The new Haleon facility in India to create up to 500 jobs, encompassing advanced positions in technical engineering, quality compliance, automated logistics, and plant administration.
Which consumer brands will be supported by this new facility?
The facility is intended to streamline the supply chain for Haleon's global health portfolio, which features world-renowned brands like Sensodyne, Panadol, and Centrum.
How does this investment impact long-term corporate sustainability?
The plant will feature modern, energy-efficient manufacturing systems, aligning with Haleon’s corporate commitments to reduce carbon emissions and localize global supply networks.
Sources: Corporate development briefings and international expansion updates published by Haleon plc., Global investment and capacity registries tracked via the Ministry of Commerce and Industry.
